Most patients with early cervical cancer are treated by radical hysterectomy followed by adjuvant chemoradiation, according to the presence of clinicopathologic risk factors ([@bib4], [@bib5]; [@bib20]; [@bib15]; [@bib23]; [@bib13]; [@bib18]). Because patients with early cervical cancer have a favourable prognosis and adjuvant radiation treatment is associated with considerable acute or chronic adverse effects, identification of this high-risk group is crucial for physicians to avoid overtreatment ([@bib20]; [@bib15]; [@bib18]). Several clinicopathologic factors, such as tumour size, histology, lymphovascular space tumour involvement (LVSI), lymph node metastasis, and parametrial involvement, have been identified and analysed for prognostic significance ([@bib4]; [@bib8]; [@bib19]).

Among these variables, several risk factors including positive lymph nodes, parametrial tumour invasion, and a positive resection margin were defined as high-risk factors because they were shown to increase the recurrence rate to 25--30%, necessitating adjuvant chemoradiation treatment ([@bib4]; [@bib8]; [@bib15]). However, intermediate-risk factors such as LVSI, large tumour size, and deep stromal invasion (DSI) do not significantly increase the recurrence rate alone, but when combined, the risk of recurrence is increased to 15--20%, which is similar to that of high-risk factors ([@bib4], [@bib5]; [@bib20]; [@bib23]; [@bib18]).

Because selecting a criterion for a risk group involves choosing a specific point in the risk spectrum, researchers or physicians can use any criterion according to the purpose of the specific study or treatment strategy (e.g., a high-risk group for relatively toxic therapeutic agents and a low-risk group for relatively non-toxic agents) ([@bib4], [@bib5]; [@bib20]; [@bib23]; [@bib18]).

According to the 'Classic criteria\', the intermediate-risk group includes patients with any two of the following three intermediate-risk factors: a) tumour size ⩾2 cm, b) LVSI, and c) stromal invasion of more than one-third of the cervical wall ([@bib4]; [@bib19]; [@bib23]; [@bib18]). Despite their simplicity and convenience, the Classic criteria provide low specificity and they are associated with a recurrence rate of 5--8% therefore, many researchers and physicians are reluctant to apply these criteria to sophisticated or toxic therapeutic agents in this patient group ([@bib19]; [@bib18]; [@bib16]).

In contrast, based on a prospective study, the Gynecologic Oncology Group (GOG) defined the intermediate-risk group using various combinations of three factors (LVSI, DSI, and tumour size). This approach resulted in the following 'GOG criteria\': a) positive capillary-LSVI, deep and middle third penetration, and clinical tumour size ⩾2 cm; b) superficial third penetration and clinical tumour size ⩾5 cm; and c) negative capillary-lymphatic space involvement with middle or deep third penetration and clinical tumour size ⩾4 cm ([@bib4], [@bib5]; [@bib20]). However, despite their complexity, the sensitivity of these criteria is low, as almost half of the recurrences occur in patients who do not meet the GOG criteria ([@bib18]). Furthermore, based on a previous study of patients with cervical cancer with only squamous cell histology, the prognostic significance of adenocarcinoma histology, which accounts for ∼25% of all cervical cancers, was excluded from the GOG criteria ([@bib4], [@bib5]; [@bib20]). Considering that the incidence of adenocarcinoma histology in cervical cancer was recently reported to be as high as 32%, the significance of adenocarcinoma histology as a prognostic variable should be thoroughly investigated ([@bib1]).

In this study, we sought to determine a new criterion to define the intermediate-risk group of patients with cervical cancer exhibiting any intermediate-risk factor after radical hysterectomy.

Materials and Methods
=====================

Patients
--------

From 1998 to 2008, 2158 patients with pathologically proven International Federation of Gynecology and Obstetrics (FIGO) stage IB--IIA cervical cancer and any intermediate-risk factor after radical hysterectomy were enrolled from 15 Korean Gynecologic Oncology Group (KGOG)-affiliated institutes.

Cervical cancer was staged according to the FIGO staging system using physical examination, chest radiography, intravenous pyelography, and abdominopelvic computed tomography (CT) or magnetic resonance imaging (MRI) findings. Cystoscopy and colonoscopy were performed if there was a suspicion of bladder or rectal involvement. Tumour size was determined by clinical palpation, inspection, or measurement of the largest diameter of the tumour using imaging modalities such as CT or MRI.

The operational record of abdominal or laparoscopic radical hysterectomy with bilateral pelvic lymphadenectomy, with or without para-aortic lymphadenectomy, was reviewed to determine the appropriateness of the surgical procedure. Pathological reports including the description of histology, DSI, LVSI, number of lymph nodes and positive nodes, parametrial tumour involvement, and tumour invasion of the resection margin were reported and reviewed. DSI was measured in reference to the fractional thickness of the cervix, which was divided into thirds. LVSI was recorded when tumour cells were identified microscopically within endothelium-lined spaces.

Patients who received neoadjuvant chemotherapy before surgery, those with a history of previous radiation therapy, those with cervical cancer found incidentally after simple hysterectomy, and those with metastatic cervical cancers were excluded.

Adjuvant treatment
------------------

Adjuvant therapy was determined by the physicians according to the guidelines for cervical cancer treatment at each institute; the treatment options included no further treatment, radiation alone, radiation therapy with chemotherapy, and chemotherapy alone. In brief, adjuvant radiation therapy was started within 4--6 weeks after surgery using a conventional four-field technique. The radiation dose ranged from 40 Gy in 23 fractions to 50.4 Gy in 28 fractions (daily fractions of 1.8--2.0 Gy (5 fractions per week) over 4.5--6 weeks). The cisplatin-based concurrent chemotherapy regimens consisted of weekly cisplatin (40 mg/m^2^) for six cycles or FP (500 mg/m^2^ 5-fluorouracil (FU)+50 mg/m^2^ cisplatin) every 3 weeks for three cycles. The systemic chemotherapy regimens consisted of CP (500 mg/m^2^ cyclophosphamide+50 mg/m^2^ cisplatin), FP (500 mg/m^2^ 5-FU+50 mg/m^2^ cisplatin), or TP (135 mg/m^2^ paclitaxel+75 mg/m^2^ cisplatin).

Follow-up
---------

At follow-up visits, patients received a physical examination, Pap smear, and squamous cell carcinoma antigen monitoring every 3 months for 2 years and then every 6 months for the next 3 years. Chest radiography and imaging modalities such as CT, positron emission tomography (PET), or PET/CT were performed every 6 months for the first 2 years and then annually for the next 3 years.

Disease recurrence was defined as the histological presence of tumour cells by biopsy or fine-needle aspiration cytology, any lymph node \>1 cm along the short axis diameter on the CT scan, or an increase in tumour size\>30% on the follow-up CT scan.

All medical records were collected according to the KGOG 1021 protocol and case report forms approved by each institutional review board, which waived the requirement for informed consent.

Statistics
----------

### Development group and validation group

A total of 2158 patients were included in this analysis. These subjects were randomly divided into development and validation groups at a 3:1 allocation ratio. Models were developed using the development group and validated using the validation group.

### Selection of prognostic variables

The association between clinicopathologic parameters was examined using the *χ*^2^-test with the Yates continuity correction for 2 × 2 tables, Fisher\'s exact test, and the Pearson correlation test, as appropriate. Disease-free survival was estimated using the Kaplan--Meier method. Survival curves were compared using the log-rank test. Trend tests were performed for ordinal scale categorical variables. The Cox proportional hazards regression model was used to estimate the hazard ratio of risk factors.

To develop prediction models for recurrence, univariate and multivariate Cox regression models were employed. FIGO stage, histology, tumour size, DSI, LVSI, and adjuvant treatment were considered in the analyses.

Tumour size was categorised as 2, 3, 4, or 5 cm, and DSI variables were stratified using 2 cutoff values (middle third or more and outer third).

### Abbreviations and development of models

To simplify the name of each factor, we used the following abbreviations: ADE, adenocarcinoma or adenosquamous carcinoma histology; 2CM, tumour size⩾2 cm; 3CM, tumour size⩾3 cm; 4CM, tumour size⩾4 cm; 5CM, tumour size⩾5 cm; MID, stromal invasion⩾ the middle third of the cervical wall; and OUT, stromal invasion of the outer third of the cervical wall.

For the selection of variables for the models, we validated the statistical significance of all possible combinations of factors, including two-factor models, any two factors among three-factor models, and any two or three factors among four-factor models.

As the four-factor model performed better than the two- and three-factor models, we only presented the results of the four-factor models, which we termed Models 1--9.

### Evaluation of the performance of the models

To evaluate the performance of the models with respect to their discrimination ability, two statistics were used: chi-square values from the log-rank test and C-statistics from the receiver operating characteristic (ROC) analysis.

All analyses were performed using SAS v.9.0 and SPSS v.18.

Results
=======

Demographic characteristics
---------------------------

The median age of the participants was 49.3 years (range, 19.7--83 years). Stage IB1 disease (76.7%) was the most common, followed by stage IB2 (11.7%) and stage IIA (11.5%) disease. Squamous cell carcinoma was the most common histologic cell type (76.2%), followed by adenocarcinoma (16.7%) and adenosquamous carcinoma (4.8% [Table 1](#tbl1){ref-type="table"}).

The median tumour size was 2.8 cm (range, 1--7 cm), and the distribution of the extent of DSI was even (inner third, 36.6% middle third, 29.1% and outer third, 34.3%). Positive LVSI was found in 31.2% of the patients ([Table 1](#tbl1){ref-type="table"}).

The development and validation groups did not differ significantly in terms of age, stage, tumour size, or distribution of intermediate-risk factors ([Table 1](#tbl1){ref-type="table"}).

Two-thirds of patients met the Classic criteria (63.8%), whereas 36.1% of patients met the GOG criteria. More than 70% of patients were observed without any adjuvant treatment, but 26.2% of patients required treatment, which primarily consisted of chemoradiation or radiation only (20.4%) and systemic chemotherapy (5.8% [Table 1](#tbl1){ref-type="table"}).

The development and validation groups did not differ significantly with regard to risk factor distribution, and 64% and 35% of patients met the Classic and GOG criteria, respectively ([Table 1](#tbl1){ref-type="table"}).

After a median follow-up time of 64.2 months, 131 recurrences (8.1%) were noted, and 78 patients died of the disease (4.8%) in the development group; these values were not significantly different from those of the validation group (recurrence rate, 8.2% and death rate, 5% [Table 1](#tbl1){ref-type="table"}).

Pattern of recurrence
---------------------

There were 175 recurrences (8.1%) among the 2158 patients. There was no statistically significant difference in the number of recurrences between the no further treatment group (8.1%) and those who received radiation therapy or chemoradiation (8.2%). However, the recurrence rate was higher in patients who received adjuvant chemotherapy (19.5%, *P*\<0.05; [Table 2](#tbl2){ref-type="table"}). There was no statistically significant difference in the number of recurrent sites among the three groups ([Table 2](#tbl2){ref-type="table"}).

Selection of models for discriminating the intermediate-risk group
------------------------------------------------------------------

FIGO stage, histology, tumour size, DSI, LVSI, and adjuvant treatment were significantly associated with disease-free survival in the univariate analysis, but FIGO stage and adjuvant treatment were not significantly associated with disease-free survival in the multivariate analysis ([Table 3](#tbl3){ref-type="table"}).

After excluding FIGO stage and adjuvant treatment as prognostic variables, nine models were established via various combinations of four variables (histology, tumour size, DSI, and LVSI) that exhibited statistical significance in multivariate analysis, and their significance was compared with the Classic and GOG criteria ([Table 4](#tbl4){ref-type="table"}).

Among the nine models, Model 2 (any two factors among 3CM, OUT, LVSI, and ADE) exhibited the highest chi-square score (40.48) in the log-rank test, followed by Model 4 (any three factors among 2CM, OUT, LVSI, and ADE; chi-square value, 39.33) and Model 5 (any three factors among 3CM, OUT, LVSI, and ADE; chi-square value, 36.47; [Table 4](#tbl4){ref-type="table"}). In addition to Models 2, 4, and 5, the other any two- or any three-factor models displayed higher chi-square scores than the Classic and GOG criteria (14.95 and 25.55, respectively).

All of the analyses were duplicated in the no further treatment only group, which did not receive any adjuvant treatment, and the highest chi-square value was observed in Model 2 ([Table 4](#tbl4){ref-type="table"}).

Performance analysis of models
------------------------------

Performance analysis for predicting recurrence among the 11 models, including the Classic and GOG criteria, revealed that Model 2 displayed the best performance among the various models (*C*-value, 0.634), as confirmed in a separate analysis in the validation group (*C*-value, 0.686; [Table 5](#tbl5){ref-type="table"}).

Receiver operating characteristic curve analysis also confirmed that Model 2 performed the best among the four-factor models, as well as markedly better than the Classic and GOG criteria ([Figure 1](#fig1){ref-type="fig"}).

Discussion
==========

This study demonstrated that our 'four-factor model\' including any two of four intermediate-risk factors (3CM, LVSI, OUT, and ADE) could predict recurrence and survival more effectively than other criteria in patients with intermediate-risk factors after radical hysterectomy.

According to the Classic criteria, the intermediate-risk group is defined by the presence of any two factors among three variables (2CM, MID, and LVSI) ([@bib4]; [@bib19]; [@bib23]; [@bib18]). Despite their simplicity and convenience, the Classic criteria define the intermediate-risk group rather liberally, resulting in a relatively low specificity for predicting recurrence and survival ([@bib18]), which decreases the general performance of the criteria ([Table 4](#tbl4){ref-type="table"}). In contrast, the GOG criteria define the intermediate-risk group more strictly than the Classic criteria, as they include various combinations of the three factors (LVSI, DSI, and tumour size); however, these criteria are too complex and inconvenient, and they demonstrate low sensitivity and are poor predictors of recurrence and survival ([Table 4](#tbl4){ref-type="table"}) ([@bib4]; [@bib20]; [@bib18]).

Our results indicate that the 'four-factor model,\' which defines the intermediate-risk group according to the presence of any two of four risk variables (tumour size, DSI, LVSI, and histology), is a better predictor of recurrence and survival compared with previous criteria. We postulate that this difference in performance arises primarily from the inclusion of histologic cell type as an intermediate-risk factor, which was ignored in previous studies ([@bib4], [@bib5]; [@bib20]; [@bib23]).

In general, adenocarcinomas of the cervix are considered to be more difficult to detect because they are detected at a more advanced stage and they metastasise earlier, resulting in a poorer prognosis, than similar-stage squamous cell cervical cancer tumours ([@bib6]; [@bib7]; [@bib14]; [@bib11]; [@bib17]; [@bib10]; [@bib12]). Adenocarcinomas of the cervix are also more resistant to radiation therapy due to the presence of highly cycling cells, including a high proportion of residual radioresistant cells, compared with squamous cell cancer ([@bib6]; [@bib21]). However, in the intermediate-risk group of patients with cervical cancer who have a favourable prognosis, the statistical significance of histologic type has been ignored in many reports and clinical trials ([@bib4], [@bib5]; [@bib20]; [@bib7]; [@bib23]; [@bib17]). Our results demonstrated that histologic cell type has significant prognostic value, and if included as an intermediate-risk factor, it could dramatically improve the performance of criteria for defining the intermediate-risk group among patients with early cervical cancer after radical hysterectomy.

Tumour size is strongly correlated with recurrence and survival in cervical cancer after radical hysterectomy ([@bib4]; [@bib2]; [@bib22]; [@bib9]; [@bib3]) ([Tables 3](#tbl3){ref-type="table"}, [4](#tbl4){ref-type="table"}). In general, 2CM is correlated with an increased risk of recurrence ([@bib4]; [@bib3]), but our study and others indicate that 3CM is better correlated with recurrence ([Table 5](#tbl5){ref-type="table"}).

The measurement of tumour size in cervical cancer is frequently debated. Currently, several methods have been proposed for measuring tumour size in cervical cancer, including clinical palpation, measurement of the longest diameter on imaging modalities, the colposcopic tumour size, and measurement of the diameter of the pathologic specimen. However, each of these methods has limitations such as subjectivity, tumour shrinkage, and difficulty in measuring endocervical cancers. Currently, despite limited subjectivity, clinical tumour size determined by palpation under general anaesthesia is generally accepted as a standard method of tumour measurement in cervical cancer. In this study, because tumour size was measured primarily using imaging modalities such as MRI, we suggest that our results may be less controversial than those presented in previous studies.

Despite the retrospective nature of this study, it is the largest study to date, particularly regarding the number of patients with adenocarcinoma or adenosquamous carcinoma histology, which increases the credibility of our results. The largest published study to date included 732 cases of stage IB cervical cancer with squamous histology only ([@bib4]). The total number of patients in our study exceeded 2000, including 400 cases with adenocarcinoma or adenosquamous carcinoma histology, which was sufficient to assess the significance of the histologic cell type of cervical cancer.

This study also involved 15 institutes and encompassed a 10-year study period. Despite the possible diversity in pathologist review methods and the modality of treatment among the institutes, our results more accurately reflect the real-world clinical situation than short-term prospective studies. We do not believe that the pathologist\'s decision to determine LVSI, DSI, and histologic cell type is difficult, and the treatment of cervical cancer has changed significantly since the introduction of cisplatin-based chemoradiation in the 1990s ([@bib16]). Therefore, we believe that the confounding effect of varying pathologic review methods at each institute and changes in treatment during the study period are negligible.

In this study, over a median follow-up period of more than 60 months, the overall recurrence rate was 8.2%, which is lower than that reported in previous studies ([@bib4]; [@bib23]). The more general application of adjuvant treatment to the relatively higher risk group may have reduced the recurrence rate; however, despite adjuvant treatment, the recurrence rate did not decrease below the level of the non-adjuvant treatment group ([Table 2](#tbl2){ref-type="table"}). Moreover, although there was no statistical significance, a slight difference was observed in the recurrence pattern in the CT or CRT groups, which demonstrated lower local recurrence and higher distant metastasis rates, suggesting that adjuvant RT or CRT is a useful local control modality but does not prevent distant metastasis. Furthermore, the adjuvant chemotherapy group showed the highest recurrence rate (19.5%), strongly suggesting that adjuvant chemotherapy may not serve as an effective adjuvant treatment modality. However, because this study was not designed to investigate the role of adjuvant treatment, further studies are needed to confirm this finding. In addition, adjuvant treatment may influence recurrence and survival; however, the statistical significance of our models was not affected by the inclusion of patients who received adjuvant therapy ([Table 4](#tbl4){ref-type="table"}). Regarding the homogeneity of the study population, excluding the adjuvant treatment group seemed to be a more reasonable approach than including it, but this also biased our results by removing the relatively higher risk group of patients. [Table 4](#tbl4){ref-type="table"} presents the analysis in both ways, excluding or including the adjuvant treatment group, which ultimately produced the same results. In conclusion, our study identified a 'four-factor model\' that used the presence of any two of four risk variables (3CM, OUT, LVSI, and ADE) to define the intermediate-risk group. This model may predict recurrence and poor survival more effectively than previous criteria in patients with cervical cancer and the presence of any intermediate-risk factor after radical hysterectomy. Moreover, our model will be beneficial to researchers and physicians for selecting which group of patients should receive adjuvant treatment and for defining patient groups for clinical trials aimed at investigating more sophisticated treatment strategies.
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![**The ROC curve analysis for recurrence confirmed that Model 2 performed better than the Classic and GOG criteria (A) and other models (B).** Abbreviations: CI=confidence interval; H0=null hypothesis; Obs=observed; ROC=receiver operating characteristic.](bjc2013716f1){#fig1}

###### Demographic characteristics

                                    **Number (%) or median (range)**                      
  -------------------------------- ---------------------------------- ------------------- ----
  No. of patients                                 1620                        538           
  Age (years)                              49.3 (19.7--83.0)           48.7 (26.9--78.0)    
  **Stage**                                                                               
  IB1                                         1243 (76.7)                 416 (77.3)       ns
  IB2                                          190 (11.7)                  50 (9.3)         
  IIA                                          187 (11.5)                  72 (13.4)        
  **Histology**                                                                           
  SCC                                         1234 (76.2)                 403 (74.9)       ns
  Adeno                                        271 (16.7)                  90 (16.7)        
  Adenosquamous                                 78 (4.8)                   37 (6.9)         
  Other                                         37 (2.3)                    8 (1.5)         
  Tumour size (cm)                           2.8 (1.0--7.0)             2.7 (1.0--7.0)     ns
  **DSI**                                                                                 
  Inner 1/3                                    593 (36.6)                 183 (34.0)       ns
  Middle 1/3                                   472 (29.1)                 171 (31.8)        
  Outer 1/3                                    555 (34.3)                 184 (34.2)        
  **LVSI**                                                                                
  Positive                                     505 (31.2)                 166 (30.9)       ns
  Negative                                    1115 (68.8)                 372 (69.1)        
  **Intermediate-risk grouping**                                                          
  Classic criteria (+)                        1034 (63.8)                 344 (63.9)       ns
  GOG criteria (+)                             585 (36.1)                 190 (35.3)        
  **Adjuvant treatment**                                                                  
  Yes                                          425 (26.2)                 143 (26.6)       ns
  RT or CRT                                    331 (20.4)                 109 (20.3)        
  Chemotherapy                                  94 (5.8)                   34 (6.3)         
  No                                          1195 (73.8)                 395 (73.4)        
  Follow-up duration (months)              64.0 (0.2--234.0)           64.6 (0.2--231.0)   ns
  Recurrence                                 131/1620 (8.1)              44/538 (8.2)      ns
  Classic criteria (+)                      103/1034 (10.0)              30/344 (8.7)       
  GOG criteria (+)                           71/585 (12.1)               18/190 (9.5)       
  **Status**                                                                              
  Died                                          78 (4.8)                   27 (5.0)        ns
  Alive                                       1533 (94.6)                 510 (94.8)        

Abbreviations: CRT=concurrent chemoradiation; DSI=deep stromal invasion; GOG=Gynecologic Oncology Group; LVSI=lymphovascular space involvement; ns=not significant; RT=radiation therapy; SCC=squamous cell carcinoma.

###### Pattern of recurrence

                            **No. (%)**   **No further treatment (%)**   **RT or CRT (%)**   **Chemotherapy (%)**  ***P*****-value**
  ------------------------ ------------- ------------------------------ ------------------- ---------------------- -------------------
  No. of patients              2158                   1718                      440                  128            
  No. of recurrence          175 (8.1)             139 (8.1)                 36 (8.2)             25 (19.5)        0.0002
  **Site of recurrence**                                                                                           
  Local                      66 (3.1)               56 (3.3)                 10 (2.3)              8 (6.3)          
  Distant                    85 (3.9)               65 (3.8)                 20 (4.5)              10 (7.8)        ns
  Mixed                      24 (1.1)               18 (1.0)                  6 (1.4)              7 (5.5)          

Abbreviations: CRT=chemoradiation; ns=not significant; RT=radiation therapy.

###### Univariate and multivariate analysis of individual variables for disease-free survival

                                                                      **Univariate analysis**   **Multivariate analysis**                                               
  ----------------------------------------------- ------------------ ------------------------- --------------------------- ------------------- -------- --------------- -------------------
  **Risk factors**                                 **Abbreviation**           **HR**                   **95% CI**           ***P*****-value**   **HR**    **95% CI**     ***P*****-value**
  FIGO stage                                             ST2                   1.900                  1.229--2.937                0.004         1.482    0.940--2.339          0.091
  Adeno or adenosquamous                                 ADE                   1.469                  1.011--2.134                0.043         1.743    1.194--2.545          0.004
  Tumour size⩾2 cm                                       2CM                   4.883                  1.997--11.938               0.001         4.588    1.871--11.248         0.001
  Tumour size⩾3 cm                                       3CM                   2.756                  1.815--4.184                0.000         2.512    1.645--3.835          0.000
  Tumour size⩾4 cm                                       4CM                   1.833                  1.289--2.606                0.001         1.481    1.024--2.142          0.037
  Tumour size ⩾5 cm                                      5CM                   2.038                  1.319--3.151                0.001         1.537    0.978--2.415          0.062
  Stromal invasion ⩾middle 1/3 of cervical wall          MID                   1.845                  1.246--2.734                0.002         1.303    0.861--1.973          0.211
  Stromal invasion ⩾outer 1/3 of cervical wall           OUT                   2.020                  1.435--2.843                0.000         1.566    1.091--2.247          0.015
  LVSI positive                                          LVSI                  2.015                  1.426--2.847                0.000         1.845    1.265--2.690          0.001
  Adjuvant treatment                                     ADJ                   1.957                  1.355--2.827                0.000         1.372    0.910--2.069          0.131

Abbreviations: CI=confidence interval; FIGO=International Federation of Gynecology and Obstetrics; HR=hazard ratio; LVSI=lymphovascular space involvement.

###### Univariate analysis of various models predicting recurrence

                                 **Deveopment group (*****n*****=1620)**   **Develpment group (NFT group only,** ***n*****=1195)**   **Validation group (*****n*****=538)**                                                                                                              
  ------------------------ ----- ----------------------------------------- --------------------------------------------------------- ---------------------------------------- -------- ------- ------- ------- --------------- -------- ------- ------- ------- --------------- -------- -------
  Classic                   No                                                                                                                                                14.954   0.000                                   6.818    0.008                                   0.869    0.351
                            Yes  0.000                                     2.203                                                     1.462--3.321                                              0.010   1.808   1.152--2.839                     0.353   1.351   0.716--2.551              
  GOG                       No                                                                                                                                                25.558   0.000                                   12.833   0.001                                   1.464    0.226
                            Yes  0.000                                     2.364                                                     1.676--3.333                                              0.000   2.131   1.395--3.257                     0.229   1.447   0.792--2.644              
  **Any 2 of 4 factors**                                                                                                                                                                                                                                                                 
  2CM, OUT, LVSI, ADE       No                                                                                                                                                28.862   0.000                                   20.343   0.000                                   13.557   0.000
  (Model 1)                 Yes  0.000                                     2.911                                                     1.935--4.379                                              0.000   2.815   1.760--4.502                     0.001   3.618   1.739--7.528              
  3CM, OUT, LVSI, ADE       No                                                                                                                                                40.482   0.000                                   28.174   0.000                                   22.627   0.000
  (Model 2)                 Yes  0.000                                     3.143                                                     2.167--4.559                                              0.000   3.056   1.980--4.717                     0.000   4.528   2.288--8.964              
  4CM, OUT, LVSI, ADE       No                                                                                                                                                27.736   0.000                                   15.313   0.000                                   16.602   0.000
  (Model 3)                 Yes  0.000                                     2.438                                                     1.731--3.435                                              0.000   2.285   1.493--3.497                     0.000   3.234   1.779--5.876              
  **Any 3 of 4 factors**                                                                                                                                                                                                                                                                 
  2CM, OUT, LVSI, ADE       No                                                                                                                                                39.330   0.000                                   22.000   0.000                                   6.250    0.012
  (Model 4)                 Yes  0.000                                     2.942                                                     2.066--4.190                                              0.000   2.891   1.817--4.600                     0.015   2.201   1.167--4.151              
  3CM, OUT, LVSI, ADE       No                                                                                                                                                36.475   0.000                                   21.802   0.000                                   10.864   0.001
  (Model 5)                 Yes  0.000                                     2.993                                                     2.060--4.350                                              0.000   3.162   1.898--5.267                     0.002   2.836   1.483--5.423              
  4CM, OUT, LVSI, ADE       No                                                                                                                                                27.951   0.000                                   9.121    0.010                                   9.105    0.003
  (Model 6)                 Yes  0.000                                     2.975                                                     1.946--4.547                                              0.004   2.656   1.374--5.136                     0.004   2.939   1.410--6.127              
  **All 4 factors**                                                                                                                                                                                                                                                                      
  2CM, OUT, LVSI, ADE       No                                                                                                                                                10.365   0.001                                   2.095    0.230                                   3.459    0.063
  (Model 7)                 Yes  0.003                                     3.530                                                     1.555--8.011                                              0.165   2.703   0.665--10.990                    0.076   2.893   0.895--9.345              
  3CM, OUT, LVSI, ADE       No                                                                                                                                                13.905   0.000                                   4.134    0.120                                   5.585    0.018
  (Model 8)                 Yes  0.001                                     4.198                                                     1.848--9.535                                              0.059   3.862   0.949--15.722                    0.028   3.735   1.155--12.080             
  4CM, OUT, LVSI, ADE       No                                                                                                                                                1.764    0.184                                   0.130    0.620                                   3.953    0.047
  (Model 9)                 Yes  0.199                                     2.496                                                     0.617--10.094                                             0.810   0.050                                    0.065   3.812   0.922--15.765             

Abbreviations: 2CM=tumour size⩾2 cm; 3CM=tumour size⩾3 m; 4CM=tumour size⩾4 cm; CI=confidence interval; GOG=Gynecologic Oncology Group; HR=hazard ratio; LVSI=lymphovascular space involvement; NFT=no further treatment; OUT=stromal invasion of the outer third of the cervical wall.

###### *C*-value of each model for predicting recurrence

             **Development group (*****n*****=1620)**   **Validation group (*****n*****=538)**                          
  --------- ------------------------------------------ ---------------------------------------- ------- ------- ------- -------
  Classic                     0.581                                     0.542                   0.619    0.540   0.469   0.611
  GOG                         0.613                                     0.567                   0.659    0.555   0.475   0.634
  Model 1                     0.612                                     0.572                   0.651    0.644   0.582   0.705
  Model 2                     0.634                                     0.591                   0.677    0.686   0.620   0.752
  Model 3                     0.605                                     0.558                   0.651    0.650   0.573   0.728
  Model 4                     0.613                                     0.566                   0.659    0.658   0.580   0.736
  Model 5                     0.603                                     0.557                   0.648    0.564   0.491   0.638
  Model 6                     0.584                                     0.542                   0.627    0.586   0.513   0.659
  Model 7                     0.562                                     0.525                   0.600    0.561   0.495   0.627
  Model 8                     0.525                                     0.498                   0.553    0.567   0.504   0.629
  Model 9                     0.509                                     0.494                   0.524    0.501   0.477   0.526

Abbreviations: CI=confidence interval; GOG=Gynecologic Oncology Group.

Disease-free survival, *t*=60 months.
